Dr. Reddy's Laboratories Limited (RDY)

NYSE: RDY · IEX Real-Time Price · USD
56.34
-0.03 (-0.05%)
Mar 30, 2023, 12:43 PM EDT - Market open
-0.05%
Market Cap 9.36B
Revenue (ttm) 2.81B
Net Income (ttm) 309.29M
Shares Out 166.10M
EPS (ttm) 1.86
PE Ratio 20.86
Forward PE 20.70
Dividend $0.36 (0.65%)
Ex-Dividend Date Jul 11, 2022
Volume 44,654
Open 56.69
Previous Close 56.37
Day's Range 56.29 - 56.80
52-Week Range 49.59 - 58.28
Beta 0.24
Analysts Buy
Price Target 61.81 (+9.71%)
Earnings Date May 18, 2023

About RDY

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the bi... [Read more]

Sector Healthcare
Founded 1984
Employees 24,795
Stock Exchange NYSE
Ticker Symbol RDY
Full Company Profile

Financial Performance

In 2022, RDY's revenue was 214.39 billion, an increase of 13.00% compared to the previous year's 189.72 billion. Earnings were 23.57 billion, an increase of 36.72%.

Financial numbers in INR Financial Statements

Analyst Forecast

According to 46 analysts, the average rating for RDY stock is "Buy." The 12-month stock price forecast is $61.81, which is an increase of 9.71% from the latest price.

Price Target
$61.81
(9.71% upside)
Analyst Consensus: Buy
Stock Forecasts

News

5 Top-Ranked Dividend Stocks to Counter Market Volatility

Dr. Reddys (RDY), Darden Restaurants (DRI), Interpublic Group (IPG), Microchip Technology (MCHP) and Valero Energy (VLO) could be compelling picks amid market volatility.

Other symbols: DRIIPGMCHPVLO
1 week ago - Zacks Investment Research

Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy's Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg fu...

Other symbols: COYA
1 week ago - Business Wire

Here's Why Doctor Reddy's (RDY) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

3 weeks ago - Zacks Investment Research

3 Generic Drug Stocks to Watch Amid Macro Headwinds

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.

Other symbols: AMPHTEVA
3 weeks ago - Zacks Investment Research

Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma's U.S. Generic Prescription Product Portfolio

HYDERABAD, India & BASEL, Switzerland & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories announces agreement to acquire Mayne Pharma's U.S. generic prescription product por...

1 month ago - Business Wire

Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

1 month ago - Zacks Investment Research

Dr. Reddy's included in Bloomberg Gender-Equality Index for the 6th year in a row and S&P Global's Sustainability Yearbook for the 3rd year

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #Bloomberg--Dr. Reddy's Laboratories Ltd announced major back-to-back recognitions in gender equality and sustainability.

1 month ago - Business Wire

The 3 Most Undervalued Stocks in India for Your February Buy List

The Indian markets have been in focus with the recent Hindenburg Research report on the Adani Group. The report alleges that the group has pulled off the “largest con in corporate history.

Other symbols: HDBMMYT
2 months ago - InvestorPlace

Dr. Reddy's (RDY) Q3 Earnings & Revenues Beat Estimates

Dr. Reddy's (RDY) beat earnings and revenues in the fiscal third quarter, driven by growth in the United States and Russian markets.

2 months ago - Zacks Investment Research

Dr. Reddy's Laboratories announces the launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. R...

2 months ago - Business Wire

Dr. Reddy's successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy's”), a global pharmaceutical company, an...

2 months ago - Business Wire

New Strong Buy Stocks for January 10th

STNE, JD, VSH, MOMO and RDY have been added to the Zacks Rank #1 (Strong Buy) List on January 10 , 2023.

Other symbols: JDMOMOSTNEVSH
2 months ago - Zacks Investment Research

5 Best Emerging Markets Stocks to Buy for 2023

Here are five emerging market stocks, JD, SGML, RDY, MMYT and CPNG that are expected to gain enormously in 2023, capitalizing on their growth prospects.

Other symbols: CPNGJDMMYTSGML
3 months ago - Zacks Investment Research

Dr. Reddy's Successfully Completes Phase 1 Study of DRL_TC, a Proposed Biosimilar of Tocilizumab

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy's”), a global pharmaceutical company, an...

3 months ago - Business Wire

3 Generic Drug Stocks to Watch Amid Inflation Pressures

The impact of inflationary headwinds and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and SLGL.

Other symbols: AMPHSLGL
4 months ago - Zacks Investment Research

New Strong Buy Stocks for November 17th

PSX, DCP, RDY, PDFS and CRZBY have been added to the Zacks Rank #1 (Strong Buy) List on November 17, 2022.

Other symbols: DCPPDFSPSX
4 months ago - Zacks Investment Research

Doctor Reddy's (RDY) is a Top-Ranked Momentum Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

4 months ago - Zacks Investment Research

Dr. Reddy's (RDY) Earnings & Revenues Trump Estimates in Q2

Dr. Reddy's (RDY) earnings and sales beat estimates in second-quarter fiscal 2023.

5 months ago - Zacks Investment Research

World Economic Forum Recognises Dr. Reddy's Hyderabad Factory as Part of its Global Lighthouse Network

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #4IR--World Economic Forum recognises Dr. Reddy's Hyderabad factory as part of its Global Lighthouse Network.

6 months ago - Business Wire

Doctor Reddy's (RDY) is a Top-Ranked Value Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

6 months ago - Zacks Investment Research

3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure

The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.

Other symbols: SLGLTEVA
7 months ago - Zacks Investment Research

Dr. Reddy's Laboratories Announces the Launch of Lenalidomide Capsules in the U.S. With Two of Six Strengths Eligible for First-to-market, 180-day Exclusivity

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Affordablemedicines--Dr. Reddy's Laboratories Ltd. today announced the launch, in the U.S. market, of Lenalidomide Capsules.

7 months ago - Business Wire

Plaintiff in first Zantac lawsuit set for trial drops case

The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants.

Other symbols: GSK
8 months ago - Reuters

Doctor Reddy's (RDY) is a Top-Ranked Growth Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

8 months ago - Zacks Investment Research

Dr. Reddy's (RDY) Q1 Earnings Increase Y/Y, Sales Increase

Dr. Reddy's (RDY) earnings and sales increase year over year in first-quarter fiscal 2023.

8 months ago - Zacks Investment Research